In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH) and raised the price target from $77.00 to $97.00.
Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism.
The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the 'views from the field' represent a true drug effect.”
Fred may be the best contrarian indicator in yahoo message board history. Fred could you post more plays please? I'm making a fortune off you.
FDA Home3 Developing Products for Rare Diseases & Conditions4 -
Generic Name: cannabidiol
Trade Name: n/a
Date Designated: 02-27-2014
Orphan Designation: Treatment of Lennox-Gastaut syndrome
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sponsor: GW Pharma Ltd.
Porton Down Science Park
Salisbury, Wiltshire SP4 OJQ
What price did you short? I'll hang up and listen.
LOL!!! Where is that clown today? Maybe he is tattle tailing on his Mom taking it up the #$%$ from dix4ya666
Hey Hedgefund, nice to meet you or I guess according to Paul be you.